Nationales Centrum für Tumorerkrankungen (NCT)
Research facility
Location:
Heidelberg, Dresden, Berlin, Essen, Köln, Würzburg, Erlangen, Regensburg, Augsburg, Tübingen, Stuttgart, Ulm,
Germany (DE)
ISNI: 0000000088550365
ROR: https://ror.org/01txwsw02
Nab-paclitaxel improves disease-free survival in early breast cancer: GBG 69–Geparsepto (2019)
Untch M, Jackisch C, Schneeweiss A, Schmatloch S, Aktas B, Denkert C, Schem C, et al.
Journal article
Intratumoral RNA-based TLR-7/-8 and RIG-I agonist CV8102 alone and in combination with anti-PD-1 in a Phase I dose-escalation and expansion trial in patients with advanced solid tumors (2019)
Eigentler T, Krauss J, Schreiber J, Weishaupt C, Terheyden P, Heinzerling L, Mohr P, et al.
Conference contribution
Clinical relevance of comprehensive genomic analysis in patients with advanced-stage neuroendocrine neoplasms: Results from the MASTER trial of the German Cancer Consortium (2019)
Kreutzfeldt S, Apostolidis L, Oles M, Horak P, Heilig CE, Heining C, Hutter B, et al.
Conference contribution
Influence of PIK3CA mutations on breast cancer proliferation, lymphocyte infiltration and clinical outcome: Pooled analysis of 484 patients from three prospective multicentre GBG trials (2019)
Jank P, Loibl S, Fasching P, Karn T, Marme F, Mueller V, Schem C, et al.
Conference contribution
SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer (2019)
Xue Y, Meehan B, Fu Z, Wang XQD, Fiset PO, Rieker R, Levins C, et al.
Journal article
Fatal events during clinical trials: an evaluation of deaths during breast cancer studies (2019)
Furlanetto J, von Minckwitz G, Lederer B, Möbus V, Schneeweiss A, Huober J, Fasching P, et al.
Journal article
Treatment Strategies Derived from Comprehensive Genomic and Transcriptomic Analysis in Patients with Advanced-Stage Neuroendocrine Neoplasms: Results from the MASTER Trial of the German Cancer Consortium (2019)
Apostolidis L, Kreutzfeldt S, Oles M, Heining C, Hutter B, Gieldon L, Lamping M, et al.
Conference contribution
Evaluation of the MammaTyperVR as a molecular predictor for pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) and outcome in patients with different breast cancer (BC) subtypes (2018)
Fasching P, Laible M, Weber KE, Wirtz RM, Denkert C, Schlombs K, Schmatloch S, et al.
Conference contribution
Validation of the MammaTyper (R) pathological complete response (pCR)-score as a predictor for response after neoadjuvant chemotherapy (NACT) in patients with early breast cancer (BC) (2018)
Fasching P, Laible M, Weber KE, Wirtz RM, Denkert C, Schlombs K, Schmatloch S, et al.
Conference contribution
Prospective genome and transcriptome sequencing in advanced-stage neuroendocrine neoplasms (2018)
Apostolidis L, Kreutzfeldt S, Oles M, Gieldon L, Heining C, Horak P, Hutter B, et al.
Conference contribution